Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

OBJECTIVES: To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics. METHODS: This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Miyasaka, Nobuyuki, Mukai, Masaya, Matsubara, Tsukasa, Uchida, Shoji, Akama, Hideto, Kupper, Hartmut, Arora, Vipin, Tanaka, Yoshiya
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2014
Teme:
Clinical and Epidemiological Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151516/
https://ncbi.nlm.nih.gov/pubmed/23316080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2012-202433
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items